Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11630)	8/9/2018 10:33:45 AM
From: Biotech Jim	Read Replies (1) \| Respond to of 12215

I have a small position in PIRS, but am a cautious holder. I continue to worry about antibody formation for the anti-calins. I agree with your views on the two programs regarding the return of the SNY and the Roche rights. Roche in particular has a very high bar for progressing programs in the clinic.

To: tuck who wrote (11630)	11/7/2018 10:29:18 AM
From: tuck	Read Replies (1) \| Respond to of 12215

PIRS more mature programs remain on track Ha. Readouts due this quarter pushed into next quarter or so, per 3Q report. Stock getting zinged. Overdone, or a sign that enrollment is slow, and that further development will be slow, and that the programs will become irrelevant? Price action says the latter. Need to listen to the webcast. From PR: >>PRS-343: The Company continues to enroll and treat patients in a Phase I dose-escalation study of PRS-343, a 4-1BB/HER2 bispecific for HER2-positive solid tumors, and now intends to report initial data from the study in the first half of 2019, after completing the dose escalation, in order to provide a more comprehensive data set. Our objective for the remaining enrollment will be to favor patient selection across a range of immunotherapy-responsive tumor types. The Company is screening patients for the 11 cohort of the study, a dose level comparable to approved dose levels of trastuzumab. In August, Pieris initiated a trial with PRS-343 in combination with atezolizumab, and the Company intends to report data from this trial in 2019.<< I gather from from biotweets about the CC they are looking for higher dose cohorts still, implying they haven't hit MTD yet. Sigh, hopefully combo therapy works better, but it'll be some time before we know. Arrgh. Cheers, Tuck